RxDoctor Payments Data

Rick Hummel, MD

Internal Medicine · St Louis, MONPI 1609955483

Payments from drug & device makers

$12,284in general payments, 2019–2025

Across 738 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$972
  • AstraZeneca$844
  • Novartis$830
  • Lilly USA, LLC$802
  • Otsuka America Pharmaceutical, Inc.$735
  • Paratek Pharmaceuticals, Inc.$686
  • plus $7K from 51 others

What the payments were for

  • Food & beverage$12,20899%
  • Education$751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK61$972
AstraZeneca(2 entities)47$844
Novartis51$830
Lilly USA, LLC45$802
Otsuka America Pharmaceutical, Inc.43$735
Paratek Pharmaceuticals, Inc.37$686
Merck40$661
Jazz Pharmaceuticals Inc.21$651
AbbVie(2 entities)33$578
Novo Nordisk33$570
EMD Serono, Inc.65$558
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC29$454
Pfizer25$398
Mylan Specialty L.p.20$371
Amarin Pharma, Inc.21$309
Dexcom, Inc.14$267
Astellas Pharma US Inc15$250
UCB, Inc.11$225
Johnson & Johnson11$187
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)9$153
Exact Sciences7$139
Kowa Pharmaceuticals America, Inc.6$124
Sunovion Pharmaceuticals Inc.13$121
Sanofi-aventis U.S. LLC5$90
Hikma Pharmaceuticals USA5$84
Bayer5$83
Alkermes, Inc.3$82
Biohaven Pharmaceutical Holding Company Ltd.4$73
Valinor Pharma, LLC4$72
Boehringer Ingelheim4$64
Takeda Pharmaceuticals U.S.A., Inc.3$62
Sumitomo Pharma America, Inc.5$61
Arbor Pharmaceuticals, Inc.5$60
Lundbeck LLC3$55
Neurelis, Inc.3$53
Eisai Inc.3$50
Baxter Healthcare2$49
Vertex2$46
Phathom Pharmaceuticals, Inc.3$46
Collegium Pharmaceutical, Inc.2$33
Teva Pharmaceuticals USA, Inc.2$32
Smith+Nephew2$30
Ironwood Pharmaceuticals, Inc2$28
Acerus Pharmaceuticals Corporation1$26
Abbott1$24
Mannkind Corporation1$22
Viatris Specialty LLC1$21
Eyevance Pharmaceuticals LLC1$19
Idorsia Pharmaceuticals US Inc1$19
Protega Pharmaceutials Inc1$18
Ardelyx, Inc.1$17
Flowonix Medical Incorporated1$16
Medtronic1$14
Amgen1$13
Biohaven Pharmaceuticals, Inc.1$13
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)1$12
Shire North American Group Inc1$12

How this compares

$12,284 in reported general payments places this provider in the 95th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$257,771
Medicare patients
298
Services billed
2,122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban250$118,176
EntrestoSacubitril/Valsartan160$110,910
OzempicSemaglutide103$97,063
JanuviaSitagliptin Phosphate92$67,227
XareltoRivaroxaban95$46,463
JardianceEmpagliflozin66$42,137
MyrbetriqMirabegron91$33,871
XolairOmalizumab12$32,705
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$31,259
FarxigaDapagliflozin Propanediol63$27,982
TrulicityDulaglutide14$25,138
RexultiBrexpiprazole17$23,358
MounjaroTirzepatide14$22,918
LinzessLinaclotide37$19,036
Tresiba Flextouch U-100Insulin Degludec22$16,040

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$398$118,176250 claims
NovartisEntresto$830$110,910160 claims
Novo NordiskOzempic$570$97,063103 claims
MerckJanuvia$661$67,22792 claims
Johnson & JohnsonXarelto, Invokana$187$51,003109 claims
Lilly USA, LLCTrulicity, Mounjaro$802$48,05628 claims
Boehringer IngelheimJardiance$64$42,13766 claims
GSKTrelegy Ellipta, Shingrix$972$41,19594 claims
AstraZenecaFarxiga, Breztri Aerosphere$844$34,75774 claims
Astellas Pharma US IncMyrbetriq$250$33,87191 claims
Otsuka America Pharmaceutical, Inc.Rexulti$735$23,35817 claims
AbbVieLinzess$578$19,03637 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in St Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →